Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 676 (ZNF676) is a hominoid-specific member of the KRAB zinc finger protein (KZFP) family functioning primarily as a DNA-binding transcription factor and transcriptional repressor[2][4][6]. It binds with sequence specificity, through its KRAB and C2H2-type zinc finger domains, to long terminal repeat (LTR) sequences of endogenous retroviruses (notably LTR12C) and represses their transcriptional activity, thereby regulating gene networks crucial in early embryonic development and gametogenesis[2]. ZNF676 is also implicated in the maintenance of epigenetic marks—its binding coincides with protection of certain genomic loci (e.g., LTR12 elements) from demethylation during germ cell development, with downstream effects on gene expression inheritance[2]. Genome-wide association studies have linked variants near ZNF676 to leukocyte telomere length, and emerging data highlight its relevance in telomere biology, age-related disease risk, and reproductive function[5]. There are no known approved drugs targeting ZNF676, nor are there established clinical safety concerns associated with targeting this gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 676 (ZNF676).